RxDoctor Payments Data

James Freeman, MD

Gynecology · Lawrenceville, GANPI 1386692812

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $583 of the $676 with a category attached, or 86.2%. 6 manufacturers reported payments, led by Mayne Pharma Commercial LLC at 44.0% of the total. Reporting peaked in 2023 at $305 and has fallen 57.7% since, to $129 in 2025. That places this record below the midpoint for gynecology clinicians in GA, where the typical reported total is $566.

$676in general payments, 2019–2025

Across 23 payments — averaging $29.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Mayne Pharma Commercial LLC$297
  • Amgen$249
  • Astellas Pharma US Inc$80
  • Radius Health, Inc.$19
  • AbbVie$17
  • Millicent US Inc$13

What the payments were for

  • Food & beverage$58386%
  • Education$9314%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$676 in reported general payments places this provider in the 50th percentile of 119 gynecology providers in Georgia.

See all gynecology providers in Georgia

Medicare billing

Part B allowed, 2024
$64,986
Medicare patients
231
Services billed
712

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron53$57,936
Estradiol154$23,007
OzempicSemaglutide16$15,243
CombipatchEstradiol/Norethindrone Acet17$6,075
Trazodone Hcl78$2,331
Clobetasol Propionate38$1,875
ProgesteroneProgesterone, Micronized16$1,309
Gabapentin45$1,227
DottiEstradiol12$788
Escitalopram Oxalate41$497
Celecoxib16$431
Rosuvastatin Calcium22$397
Alendronate Sodium60$374
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst19$336
Fluconazole27$204

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$80$57,93653 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 119 gynecology providers in Georgia.

Other gynecology in Lawrenceville

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →